Dr. Thomas E. Padgett

Dr. Thomas E. Padgett

Principal Consultant

Conferences, talks and presentations

Economic and healthcare resource burden of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a United States system dynamics model

May 30, 2026

Poster, EASL 2026, Barcelona, Spain

This study estimates the clinical and patient burden of MASLD/MASH in the US, based on a dynamic prevalence model calibrated to NHANES-derived prevalence data for 2006-2020. Assuming the status quo continues, prevalence is predicted to rise from 104m in 2025 to 133m by 2060, with an associated 37% increase in direct costs and 39% increase in bed days.

Clinical and humanistic burden of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis in the United States: a system dynamics model

May 27, 2026

Poster, EASL 2026, Barcelona, Spain

This study estimates the clinical and patient burden of MASLD/MASH in the US, based on a dynamic prevalence model calibrated to NHANES-derived prevalence data for 2006-2020. Assuming the status quo continues, prevalence is predicted to rise from 104m in 2025 to 133m by 2060, with an associated 131% increase in the demand for liver transplantation and a 36% increase in deaths relating to the disease.

The Longevity Conundrum: Population Ageing in the UK

November 12, 2025

Poster, ISPOR EU 2025, Glasgow, UK

This study estimates the future age structure of the UK under increasing life expectancy and decreasing fertility, and relates that to changes in national revenue, spending, and healthcare usage.

The Changing Prevalence of Multicomorbid Patients in the US

November 11, 2025

Poster, ISPOR EU 2025, Glasgow, UK

This study estimates the prevalence of six interrelated diseases in the US, describing the significant overlap in the patient population, and demonstrating how the prevalence has changed across two decades.